These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 29807443)

  • 1. Targeting VEGF/VEGFRs Pathway in the Antiangiogenic Treatment of Human Cancers by Traditional Chinese Medicine.
    Zhang C; Wang N; Tan HY; Guo W; Li S; Feng Y
    Integr Cancer Ther; 2018 Sep; 17(3):582-601. PubMed ID: 29807443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
    Takahashi S
    Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Jianpi Jiedu decoction, a traditional Chinese medicine formula, inhibits tumorigenesis, metastasis, and angiogenesis through the mTOR/HIF-1α/VEGF pathway.
    Peng W; Zhang S; Zhang Z; Xu P; Mao D; Huang S; Chen B; Zhang C; Zhang S
    J Ethnopharmacol; 2018 Oct; 224():140-148. PubMed ID: 29852266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
    Tie J; Desai J
    Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pien Tze Huang inhibits tumor angiogenesis in a mouse model of colorectal cancer via suppression of multiple cellular pathways.
    Shen A; Lin J; Chen Y; Lin W; Liu L; Hong Z; Sferra TJ; Peng J
    Oncol Rep; 2013 Oct; 30(4):1701-6. PubMed ID: 23843018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor angiogenesis and anti-angiogenic therapies.
    Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
    Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of traditional Chinese medicines in osteogenesis and angiogenesis.
    Yang Y; Chin A; Zhang L; Lu J; Wong RW
    Phytother Res; 2014 Jan; 28(1):1-8. PubMed ID: 23494901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
    Song G; Li Y; Jiang G
    Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A; Libutti SK
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
    Terme M; Pernot S; Marcheteau E; Sandoval F; Benhamouda N; Colussi O; Dubreuil O; Carpentier AF; Tartour E; Taieb J
    Cancer Res; 2013 Jan; 73(2):539-49. PubMed ID: 23108136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF signal system: the application of antiangiogenesis.
    Liang X; Xu F; Li X; Ma C; Zhang Y; Xu W
    Curr Med Chem; 2014 Mar; 21(7):894-910. PubMed ID: 24059233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Jiedu Xiaozheng Yin, a Chinese herbal formula, inhibits tumor angiogenesis via downregulation of VEGF-A and VEGFR-2 expression in vivo and in vitro.
    Cao Z; Lin W; Huang Z; Chen X; Zhao J; Zheng L; Ye H; Liu Z; Liao L; Du J
    Oncol Rep; 2013 Mar; 29(3):1080-6. PubMed ID: 23254951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic.
    Epstein RJ
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):443-52. PubMed ID: 17786538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The VEGF signaling pathway in cancer: the road ahead.
    Stacker SA; Achen MG
    Chin J Cancer; 2013 Jun; 32(6):297-302. PubMed ID: 23419196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
    Cosmai L; Gallieni M; Liguigli W; Porta C
    J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of resistance to vascular endothelial growth factor blockade.
    Abdullah SE; Perez-Soler R
    Cancer; 2012 Jul; 118(14):3455-67. PubMed ID: 22086782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wenyang Huoxue Jiedu formula inhibits thin-cap fibroatheroma plaque formation via the VEGF/VEGFR signaling pathway.
    Chen S; Ye ZQ; Li ZW; Zhao CX; Chen GJ; Zhou JZ; Wang C; Huang RL; Hong YD
    J Ethnopharmacol; 2018 Jun; 219():213-221. PubMed ID: 29551453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors.
    Ishak RS; Aad SA; Kyei A; Farhat FS
    Crit Rev Oncol Hematol; 2014 May; 90(2):152-64. PubMed ID: 24355408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.